// App-Quantinova.ai

3711 : Pre-clinical combinations of ATR and PARP inhibitors: Defining target patient populations and dose schedule

Researchers

Presenter

  • John Pollard

Principal Investigators

  • Phil Reaper

  • Adele Peek

  • Stuart Hughes

  • Hakim Djeha

  • Steven Cummings

  • Karen Larbi

  • Marina Penney

  • Jim Sullivan

  • Darin Takemoto

  • Chris DeFranco

Medical Centers

  • Vertex Pharmaceuticals Inc, Abingdon, United Kingdom

  • Vertex Pharmaceuticals Inc., Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ataxia telangiectasia

  • Solid malignancies

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved